Want to see KR:000520 full AI Analyst Report?
Top Page
Samil Pharmaceutical Co., Ltd.
(000520)
Select Model
Select Model
Rating:47Neutral
Price Target:
₩7,525.00
Action:N/A
Date:10/28/26
The score is primarily weighed down by weakening fundamentals—sharp deterioration into heavy losses, consistently negative free cash flow, and rising leverage as equity declines. Technicals are mixed (some intermediate support but weaker near-term/long-term positioning), while valuation is constrained by negative earnings and no provided dividend yield.
Positive Factors
Historical Revenue Growth
Revenue growth in the 2022–2024 period indicates that the company has previously demonstrated an ability to expand its business. That historical commercial traction provides a foundation for recovery if operating execution, product demand, and profitability improve.
Negative Factors
Severe Profitability Deterioration
The swing from operating profit to deep operating losses, alongside an approximately negative 18% TTM net margin, shows that the current business model is not converting revenue into earnings. Persistent losses could weaken reinvestment capacity and erode financial resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Historical Revenue Growth
Revenue growth in the 2022–2024 period indicates that the company has previously demonstrated an ability to expand its business. That historical commercial traction provides a foundation for recovery if operating execution, product demand, and profitability improve.
Read all positive factors
Samil Pharmaceutical Co., Ltd. (000520) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩167.66B
Dividend Yield0.96%
Average Volume (3M)70.16K
Price to Earnings (P/E)―
Beta (1Y)0.04
Revenue Growth-4.54%
EPS Growth-88.02%
CountryKR
Employees585
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1763.67
Shares Outstanding21,691,810
10 Day Avg. Volume63,861
30 Day Avg. Volume70,155
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.54
Price to Sales (P/S)0.98
P/FCF Ratio-15.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Samil Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Samil Pharmaceutical Co., Ltd. is a South Korean pharmaceutical company founded in 1947 that develops, manufactures, and sells a range of healthcare products. While its portfolio includes various medicines and medical devices, it has a particular ...
Samil Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
41
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 207.44B | 210.37B | 219.70B | 196.35B | 179.68B | 134.25B |
| Gross Profit | 66.66B | 67.44B | 80.91B | 72.21B | 67.49B | 48.99B |
| EBITDA | -16.38B | -10.72B | 8.71B | 10.34B | 10.31B | 6.15B |
| Net Income | -37.53B | -34.59B | -5.63B | 1.66B | -28.29M | -5.35B |
Balance Sheet | ||||||
| Total Assets | 374.73B | 371.60B | 395.07B | 370.68B | 356.70B | 226.40B |
| Cash, Cash Equivalents and Short-Term Investments | 6.11B | 6.41B | 5.14B | 906.14M | 1.90B | 15.26B |
| Total Debt | 176.05B | 164.02B | 150.08B | 175.88B | 159.26B | 125.51B |
| Total Liabilities | 249.18B | 238.34B | 218.95B | 242.85B | 230.88B | 160.66B |
| Stockholders Equity | 125.55B | 133.26B | 176.12B | 127.83B | 125.82B | 65.75B |
Cash Flow | ||||||
| Free Cash Flow | -7.43B | -13.52B | -3.02B | -12.65B | -44.50B | -31.67B |
| Operating Cash Flow | -26.12M | -6.06B | 2.59B | 11.75B | 4.15B | 1.42B |
| Investing Cash Flow | -12.43B | -7.98B | -6.36B | -19.78B | -35.94B | -45.31B |
| Financing Cash Flow | 15.48B | 15.29B | 7.98B | 8.48B | 29.71B | 31.87B |
Samil Pharmaceutical Co., Ltd. Technical Analysis
Neutral
―
Price Trends
7307.20
Positive
6969.40
Positive
8315.05
Negative
Market Momentum
107.65
Positive
49.00
Neutral
21.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:000520, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 8115.00, equal to the 50-day MA of 7307.20, and equal to the 200-day MA of 8315.05, indicating a neutral trend. The MACD of 107.65 indicates Positive momentum. The RSI at 49.00 is Neutral, neither overbought nor oversold. The STOCH value of 21.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KR:000520.
Samil Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | ₩141.34B | 8.31 | ― | 3.18% | 7.46% | -14.42% | |
58 Neutral | ₩144.41B | 7.86 | ― | 4.70% | 6.59% | 185.66% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | ₩128.67B | 7.32 | ― | 0.30% | -17.85% | 81.91% | |
49 Neutral | ₩123.84B | 24.66 | ― | 0.97% | 14.83% | 1148.11% | |
47 Neutral | ₩167.66B | -4.41 | ― | 0.96% | -4.54% | -88.02% | |
44 Neutral | ₩117.74B | -0.85 | ― | ― | -2.43% | -234.71% |
* General Sector Average
KR:000520
Samil Pharmaceutical Co., Ltd.
7,780.00
-1,440.00
-15.62%
KR:000020
Dong Wha Pharm Co., Ltd.
5,210.00
-950.90
-15.43%
KR:001360
SAMSUNG PHARMACEUTICAL.CO.,Ltd.
1,251.00
-242.00
-16.21%
KR:214390
Kyongbo Pharmaceutical Co., Ltd.
5,180.00
-579.91
-10.07%
KR:271980
Jeil Pharmaceutical Co. Ltd.
8,830.00
-5,590.00
-38.77%
KR:293480
Hana Pharm Co., Ltd.
8,170.00
-3,145.07
-27.80%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.